Claims for Patent: 6,413,744

Summary for Patent: 6,413,744

Title:	Methods and host cells for improved cell culture
Abstract:	The invention provides improved methods of recombinant protein production in cell culture. More specifically, the invention relates to the modulation of the IGF-1 signaling pathway in cells so as to improve production characteristics.
Inventor(s):	Morris; Arvia E. (Seattle, WA), Reddy; Pranhitha (Seattle, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	09/648,667
Patent Claims:	1. An eukaryotic host cell genetically engineered to express: a gene for a protein of interest, wherein the protein of interest is expressed as an extracellular product; and at least one IGF-1 signaling pathway gene selected from the group consisting of a PKB gene and a MEK gene. 2. The host cell of claim 1 wherein the host cell is genetically engineered to express a second IGF-1-signaling pathway gene. 3. The host cell of claim 1 wherein the IGF-1-signaling pathway gene is expressed under control of a heterologous regulatory element. 4. The host cell of claim 1, wherein the protein of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble Flt3 ligand, a soluble CD40 ligand, CD39, CD30, CD27, a TEK/Ork, IL-15, a soluble IL-15 receptor, Ox 40, GM-CSF, RANKL, RANK, TRAIL, a soluble TRAIL receptor, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, calcitonin, growth hormone, insulin, insulinotropin, an insulin-like growth factor, parathyroid hormone, an interferon, superoxide dismutase, glucagon, an erythropoeitin, an antibody, glucocerebrosidase, an Fc-fusion protein, a globin, a nerve growth factor, an interleukin, and a colony stimulating factor. 5. The host cell of claim 1, wherein the host cell is further genetically engineered to express a first selectable marker. 6. The host cell of claim 1, wherein the host cell is a mammalian cell. 7. The host cell of claim 1, wherein the host cell is adapted to grow in serum-free medium. 8. The host cell of claim 3, wherein the heterologous regulatory element is a viral promoter. 9. The host cell of claim 5, wherein the gene encoding the selectable marker is adjacent to the IGF-1-signaling pathway gene. 10. The host cell of claim 6, wherein the host cell is selected from the group consisting of CHO, VERO, BHK, HeLa, CV1, MDCK, 293, 3T3, myeloma, PC12 and WI38 cells. 11. The host cell of claim 7, wherein the host cell is a CHO cell and the IGF-1-signaling pathway gene is the PKB gene. 12. The host cell of claim 7, wherein the host cell is a CHO cell and the IGF-1-signaling pathway gene is the MEK gene. 13. The host cell of claim 8, wherein the viral promoter is selected from the group consisting of a CMV promoter, an SV40 promoter, an RSV promoter and an adenoviral promoter. 14. A method of producing a protein of interest, the method comprising culturing an eukaryotic host cell genetically engineered to express: a gene for a protein of interest, wherein the protein of interest is expressed as an extracellular product; and at least one IGF-1-signaling pathway gene selected from the group consisting of a PKB gene and a MEK gene, under conditions such that the protein of interest is expressed. 15. The method of claim 14, wherein the host cell is genetically engineered to express a second IGF-1-signaling pathway gene. 16. The method of claim 14, wherein the protein of interest is selected from the group consisting of a soluble TNF receptor, a soluble IL-4 receptor, a soluble IL-1 type II receptor, a soluble Flt3 ligand, a soluble CD40 ligand, CD39, CD30, CD27, a TEK/Ork, IL-15, a soluble IL-15 receptor, Ox 40, GM-CSF, RANKL, RANK, TRAIL, a soluble TRAIL receptor, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, an IL-2 receptor, an IL-2 antagonist, alpha-1 antitrypsin, calcitonin, growth hormone, insulin, insulinotropin, an insulin-like growth factor, parathyroid hormone, an interferon, superoxide dismutase, glucagon, an erythropoeitin, an antibody, glucocerebrosidase, an Fc-fusion protein, a globin, a nerve growth factor, an interleukin, and a colony stimulating factor. 17. The method of claim 14, wherein the host cell is further genetically engineered to express a first selectable marker. 18. The method of claim 14, wherein the host cell is a mammalian cell. 19. The method of claim 14, wherein the host cell is cultured in serum-free medium. 20. The method of claim 14, wherein the host cell is a CHO cell and the IGF-1-signaling pathway gene is the PKB gene. 21. The method of claim 14, wherein the host cell is a CHO cell and the IGF-1-signaling pathway gene is the MEK gene. 22. The method of claim 15, further comprising collecting the protein of interest. 23. The method of claim 15, wherein at least one of the first or second IGF-1-signaling pathway genes is expressed under control of a heterologous element. 24. The method of claim 17, wherein the gene encoding the selectable marker is adjacent to the IGF-1-signaling pathway gene. 25. The method of claim 18, wherein the host cell is selected from the group consisting of CHO, VERO, BHK, HeLa, CV1, MDCK, 293, 3T3, myeloma, PC12 and WI38. 26. The method of claim 19, wherein the medium is growth-factor free. 27. The method of claim 19, wherein the medium is protein-free. 28. The method of claim 23, wherein the heterologous regulatory element is a viral promoter. 29. The method of claim 27, wherein the medium is peptone-free. 30. The method of claim 28, wherein the viral promoter is selected from the group consisting of a CMV promoter, an SV40 promoter, an RSV promoter and an adenoviral promoter. 31. A method of producing an eukaryotic cell for production of a protein of interest, the method comprising genetically engineering an eukaryotic cell to express a gene that encodes the protein of interest, wherein the protein of interest is expressed as an extracellular product, and to express at least one IGF-1-signaling pathway gene selected from the group consisting of a PKB gene and a MBK gene. 32. A method of producing a mammalian cell line capable of growth in serum-free medium, the method comprising exposing cells that have been genetically engineered to overexpress at least one IGF-1 signaling pathway gene selected from the group consisting of a PKB gene and a MEK gene to serum-free medium, and isolating a cell line that grows in serum-free medium. 33. The method of claim 32, further comprising exposing the cells to peptone-free medium, and isolating a cell line that grows in peptone-free medium. 34. The method of claim 32, further comprising exposing the cells to protein-free medium, and isolating a cell line that grows in protein-free medium. 35. The method of any one of claims 32 to 34, wherein the IGF-1 signaling pathway gene is the PKB gene. 36. The method of any one of claims 32 to 34, wherein the IGF-1 signaling pathway gene is the MEK gene. 37. The method of any one of claims 32 to 34, wherein the cell is genetically engineered to overexpress at least two IGF-1 signaling pathway genes. 38. The method of claim 37, wherein the second IGF-1 signaling pathway gene is selected from the group consisting of a PKB gene, a MEK1 gene, a MEK2 gene, a glut5 gene, a glut1 gene, an ERK1 gene, an ERK2 gene, a JNK gene, a 14-3-3 protein gene, an IRS-1 gene, a PDK gene, and a PI3 kinase gene. 39. A method of producing an eukaryotic cell for production of a protein of interest, the method comprising genetically engineering an eukaryotic cell to express the protein of interest, wherein the protein of interest is expressed as an extracellular product, and wherein the eukaryotic cell has been genetically engineered to express an IGF-1 signaling pathway gene selected from the group consisting of a PKB gene and a MEK gene. 40. A method of producing an eukaryotic cell for production of a protein of interest, the method comprising genetically engineering an eukaryotic cell to express an IGF-1 signaling pathway gene selected from the group consisting of a PKB gene and a MEK gene, wherein the eukaryotic cell expresses the protein of interest, wherein the protein of interest is expressed as an extracellular product.

Details for Patent 6,413,744

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-08-25